Last reviewed · How we verify
Cladribine and pegylated interpheron alpha-2a — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Cladribine and pegylated interpheron alpha-2a (Cladribine and pegylated interpheron alpha-2a) — Hospital Virgen de la Salud.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cladribine and pegylated interpheron alpha-2a TARGET | Cladribine and pegylated interpheron alpha-2a | Hospital Virgen de la Salud | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cladribine and pegylated interpheron alpha-2a CI watch — RSS
- Cladribine and pegylated interpheron alpha-2a CI watch — Atom
- Cladribine and pegylated interpheron alpha-2a CI watch — JSON
- Cladribine and pegylated interpheron alpha-2a alone — RSS
Cite this brief
Drug Landscape (2026). Cladribine and pegylated interpheron alpha-2a — Competitive Intelligence Brief. https://druglandscape.com/ci/cladribine-and-pegylated-interpheron-alpha-2a. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab